Company

Bank

Analyst

Coverage

Opinion

Wk chg

3/28 cls

Endocyte Inc. (NASDAQ:ECYT)

Leerink Partners

Howard Liang

Price target

Market perform

-22%

$21.96

Wedbush

Gregory Wade

Price target

Outperform

Liang raised his target to $28 from $18 after EMA's CHMP recommended conditional approval of Vynfinit vintafolide to treat folate receptor-positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (see "Ebb & Flow," Ax). Endocyte also reported that Vynfinit plus docetaxel met the primary endpoint of progression-free survival (PFS) in the Phase IIb TARGET trial as second-line treatment of non-small cell lung cancer (NSCLC). Liang noted that the PFS signal was "relatively modest" and said it is too early to tell whether it will translate to an overall survival (OS) benefit in Phase III testing. Vynfinit is a folate (vitamin B9) linked to alkaloid chemotherapy agent desacetylvinblastine monohydrazide.